Acknowledgements The author thanks Morten Donsmark and Tine Bkdal (both Novo Nordisk A/S, Sborg, Denmark), and Kazushiro Fujiwara, and Eirik Quamme Bergan (both Novo Nordisk Pharma Ltd, Tokyo, Japan) for reviewing the manuscript, and to Andy Bond of Spirit Medical Communications Group Ltd for medical writing and editorial assistance (funded by Novo Nordisk A/S, Sborg, Denmark)
For urgent medical concerns that are not emergencies, contact NHS 111 for advice
Supporting Weight Loss Beyond Medication Although medication can play a powerful role in appetite regulation, long-term success often depends on supportive lifestyle habits alongside medication
The company's FAQ also describes a clinical maximum of 8 doses per month for PT-141, which the company states is "established in FDA guidelines for the brand-name version (Vyleesi)." The dosing limitation exists because PT-141 can temporarily affect blood pressure